Oncología Médica Traslacional y Terapia Individualizada del Cáncer

Farge, D; Frere, C; Connors, JM; Khorana, AA; Kakkar, A; Ay, C; Munoz, A; Brenner, B; Prata, PH; Brilhante, D; Antic, D; Casais, P; Esposito, MCG; Ikezoe, T; Abutalib, SA; Meillon-Garcia, LA; Bounameaux, H; Pabinger, I; Douketis, J.

2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

LANCET ONCOLOGY. 2022; 23(7): 334-347 Nº de citas: 41

Vicente-Valor, J; Escudero-Vilaplana, V; Collado-Borrell, R; Lopez-Lopez, C; Villanueva-Bueno, C; Revuelta-Herrero, JL; Ruiz-Briones, P; Somoza-Fernandez, B; Herranz, A; Sanjurjo, M.

Potential negative pharmacodynamic interaction of spironolactone and abiraterone in two prostate cancer patients

JOURNAL OF ONCOLOGY PHARMACY PRACTICE. 2022; 28(5): 1259-1263 Nº de citas: 5 [doi:10.1177/10781552221074621]

Santonja Á; Moya-García AA; Ribelles N; Jiménez-Rodríguez B; Pajares B; Fernández-De Sousa CE; Pérez-Ruiz E; Del Monte-Millán M; Ruiz-Borrego M; de la Haba J; Sánchez-Rovira P; Romero A; González-Neira A; Lluch A; Alba E.

Role of germline variants in the metastasis of breast carcinomas.

Oncotarget. 2022; 13: 843-862 Nº de citas: 1 [doi:10.18632/oncotarget.28250]

Chauhan, J; Aasaithambi, S; Marquez-Rodas, I; Formisano, L; Papa, S; Meyer, N; Forschner, A; Faust, G; Lau, M; Sagkriotis, A.

Understanding the Lived Experiences of Patients With Melanoma: Real-World Evidence Generated Through a European Social Media Listening Analysis

Jmir Cancer. 2022; 8(2): Nº de citas: 6 [doi:10.2196/35930]

Garcia-Sanchez, S; Collado-Borrell, R; Gonzalez-Haba, E; Revuelta-Herrero, JL; Escudero-Vilaplana, V; Marzal-Alfaro, MB; Sanchez-Fresneda, MN; Mur-Mur, A; Herranz, A; Martin, M; Sanjurjo, M.

A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application

Frontiers in Oncology. 2022; 12: Nº de citas: 3 [doi:10.3389/fonc.2022.889575]

Jimenez-Fonseca, P; Gallardo, E; Arija, FA; Blanco, JM; Callejo, A; Lavin, DC; Rivas, MC; Mosquera, J; Rodrigo, A; Morillas, RS; Gonzalez, MV; Munoz, A; Carmona-Bayonas, A.

Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence

EUROPEAN JOURNAL OF INTERNAL MEDICINE. 2022; 100: 33-45 Nº de citas: 10 [doi:10.1016/j.ejim.2022.02.020]

Bellmunt, J; Valderrama, BP; Puente, J; Grande, E; Bolos, MV; Lainez, N; Vazquez, S; Maroto, P; Climent, MA; del Muro, XG; Arranz, JA; Duran, I.

Recent therapeutic advances in urothelial carcinoma: A paradigm shift in disease management

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 174: Nº de citas: 11 [doi:10.1016/j.critrevonc.2022.103683]

Kopetz, S; Grothey, A; Van Cutsem, E; Yaeger, R; Wasan, H; Yoshino, T; Desai, J; Ciardiello, F; Loupakis, F; Hong, YS; Steeghs, N; Guren, TK; Arkenau, HT; Garcia-Alfonso, P; Belani, A; Zhang, X; Tabernero, J.

Quality of life with encorafenib plus cetuximab with or without binimetinib treatment in patients with BRAF V600E-mutant metastatic colorectal cancer: patient-reported outcomes from BEACON CRC

Esmo Open. 2022; 7(3): Nº de citas: 10 [doi:10.1016/j.esmoop.2022.100477]

Pacheco-Barcia, V; Munoz, A; Castro, E; Ballesteros, AI; Marquina, G; Gonzalez-Diaz, I; Colomer, R; Romero-Laorden, N.

The Homologous Recombination Deficiency Scar in Advanced Cancer: Agnostic Targeting of Damaged DNA Repair

Cancers. 2022; 14(12): Nº de citas: 13 [doi:10.3390/cancers14122950]

Martin, M; Zielinski, C; Ruiz-Borrego, M; Carrasco, E; Ciruelos, EM; Munoz, M; Bermejo, B; Margeli, M; Csoszi, T; Anton, A; Turner, N; Casas, MI; Morales, S; Alba, E; Calvo, L; De La Haba-Rodriguez, J; Ramos, M; Murillo, L; Santaballa, A; Alonso-Romero, JL; Sanchez-Rovira, P; Corsaro, M; Huang, X; Thallinger, C; Kahan, Z; Gil-Gil, M.

Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study

EUROPEAN JOURNAL OF CANCER. 2022; 168: 12-24 Nº de citas: 9 [doi:10.1016/j.ejca.2022.03.006]

Jerusalem, G; Delea, TE; Martin, M; De Laurentiis, M; Nusch, A; Beck, JT; Chan, A; Im, SA; Neven, P; Lonshteyn, A; Chandiwana, D; Lanoue, B; Fasching, PA.

Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR +/- HER2-Advanced Breast Cancer in the MONALEESA-3 Trial

CLINICAL BREAST CANCER. 2022; 22(4): 326-335 Nº de citas: 6 [doi:10.1016/j.clbc.2021.12.008]

Van Cutsem, E; Danielewicz, I; Saunders, MP; Pfeiffer, P; Argiles, G; Borg, C; Glynne-Jones, R; Punt, CJA; Van de Wouw, AJ; Fedyanin, M; Stroyakovskiy, D; Kroening, H; Garcia-Alfonso, P; Wasan, H; Falcone, A; Fougeray, R; Egorov, A; Amellal, N; Moiseyenko, V.

First-line trifluridine/tipiracil plus bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

BRITISH JOURNAL OF CANCER. 2022; 126(11): 1548-1554 Nº de citas: 6 [doi:10.1038/s41416-022-01737-2]

Bossi P; Escobar Y; Pea F.

Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice

FRONTIERS IN PAIN RESEARCH. 2022; 3: 893530-893530 Nº de citas: 7 [doi:10.3389/fpain.2022.893530]

García-Alfonso P; Lièvre A; Loupakis F; Tadmouri A; Khan S; Barcena L; Stintzing S.

Systematic review of randomised clinical trials and observational studies for patients with RAS wild-type or BRAF(V600E)-mutant metastatic and/or unresectable colorectal cancer.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022; 173: 103646-103646 Nº de citas: 7 [doi:10.1016/j.critrevonc.2022.103646]

van Mackelenbergh MT; Seither F; Möbus V; O'Shaughnessy J; Martin M; Joensuu H; Untch M; Nitz U; Steger GG; Miralles JJ; Barrios CH; Toi M; Bear HD; Muss H; Reimer T; Nekljudova V; Loibl S.

Effects of capecitabine as part of neo-/adjuvant chemotherapy - A meta-analysis of individual breast cancer patient data from 13 randomised trials including 15,993 patients.

EUROPEAN JOURNAL OF CANCER. 2022; 166: 185-201 Nº de citas: 9 [doi:10.1016/j.ejca.2022.02.003]

Cortese, S; Peligros, MI; Sola, E; Garcia-Alfonso, P; Tellado, JM.

Indocyanine green clearance test as a predictor of chemotherapy liver toxicity and post-operative complications in patients with colorectal liver metastases

CIRUGIA Y CIRUJANOS. 2022; 90(3): 310-318 Nº de citas: 1 [doi:10.24875/CIRU.21000313]

Lee, RJ; Wysocki, O; Zhou, C; Shotton, R; Tivey, A; Lever, L; Woodcock, J; Albiges, L; Angelakas, A; Arnold, D; Aung, T; Banfill, K; Baxter, M; Barlesi, F; Bayle, A; Besse, B; Bhogal, T; Boyce, H; Britton, F; Calles, A; Castelo-Branco, L; Copson, E; Croitoru, AE; Dani, SS; Dickens, E; Eastlake, L; Fitzpatrick, P; Foulon, S; Frederiksen, H; Frost, H; Ganatra, S; Gennatas, S; Glenthoj, A; Gomes, F; Graham, DM; Hague, C; Harrington, K; Harrison, M; Horsley, L; Hoskins, R; Huddar, P; Hudson, Z; Jakobsen, LH; Joharatnam-Hogan, N; Khan, S; Khan, UT; Khan, K; Massard, C; Maynard, A; McKenzie, H; Michielin, O; Mosenthal, AC; Obispo, B; Patel, R; Pentheroudakis, G; Peters, S; Rieger-Christ, K; Robinson, T; Rogado, J; Romano, E; Rowe, M; Sekacheva, M; Sheehan, R; Stevenson, J; Stockdale, A; Thomas, A; Turtle, L; Vinal, D; Weaver, J; Williams, S; Wilson, C; Palmieri, C; Landers, D; Cooksley, T; Dive, C; Freitas, A; Armstrong, AC.

Establishment of CORONET, COVID-19 Risk in Oncology Evaluation Tool, to Identify Patients With Cancer at Low Versus High Risk of Severe Complications of COVID-19 Disease On Presentation to Hospital

Jco Clinical Cancer Informatics. 2022; 6: Nº de citas: 4 [doi:10.1200/CCI.21.00177]

Benavides, M; Gomez-Espana, A; Garcia-Alfonso, P; Gonzalez, CG; Vieitez, JM; Rivera, F; Safont, MJ; Abad, A; Sastre, J; Valladares-Ayerbes, M; Carrato, A; Gonzalez-Flores, E; Robles, L; Salud, A; Alonso-Orduna, V; Montagut, C; Asensio, E; Diaz-Rubio, E; Aranda, E.

Upfront primary tumour resection and survival in synchronous metastatic colorectal cancer according to primary tumour location and RAS status: Pooled analysis of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

EJSO. 2022; 48(5): 1123-1132 Nº de citas: 4 [doi:10.1016/j.ejso.2021.11.122]